Detalhe da pesquisa
1.
Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity.
Cell
; 169(6): 1130-1141.e11, 2017 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28552348
2.
Phase III, multicenter, randomized trial of 45 Gy versus 30 Gy thoracic radiation for extensive-stage small cell lung cancer (ES-SCLC): Study protocol.
Thorac Cancer
; 15(11): 938-943, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38426233
3.
Improved Cancer-Specific Risk Stratification by the Lymph Node Ratio-Based Nomogram: A Potential Role in Guiding Postoperative Management Decisions for Oral Cavity Carcinoma.
JCO Precis Oncol
; 7: e2200365, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36603173
4.
Lymph node ratio-based nomogram for prognosis evaluation and treatment optimization of non-metastatic oral cavity squamous cell carcinoma.
Transl Oncol
; 20: 101401, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35339030
5.
Lymph node ratio-dependent prognosis stratification and postoperative radiotherapy utilization in T1-2N1 oral cavity carcinoma.
Radiother Oncol
; 172: 83-90, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35568286
6.
Spatial architecture of regulatory T-cells correlates with disease progression in patients with nasopharyngeal cancer.
Front Immunol
; 13: 1015283, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36439177
7.
Management of cervical aortic arch complicated by multiple aneurysms.
Interact Cardiovasc Thorac Surg
; 29(2): 295301, 2019 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30903156
8.
T cell receptor richness in peripheral blood increases after cetuximab therapy and correlates with therapeutic response.
Oncoimmunology
; 7(11): e1494112, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30377562
9.
STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV+ status in head and neck cancer.
Oral Oncol
; 78: 186-193, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29496049
10.
Novel Effector Phenotype of Tim-3+ Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients.
Clin Cancer Res
; 24(18): 4529-4538, 2018 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29712685
11.
Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals.
Clin Cancer Res
; 24(1): 62-72, 2018 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29061643
12.
Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer.
Oncoimmunology
; 6(1): e1261779, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28197389
13.
PD-1 Status in CD8+ T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer.
Cancer Res
; 77(22): 6353-6364, 2017 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28904066
14.
Tumor-infiltrating Tim-3+ T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk.
Oncoimmunology
; 5(10): e1200778, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27853635